Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

The current invention relates to the treatment of cancer. In particular the invention relates to modulating the anti-tumor immunity in a cancer patient. The disclosed invention is in particular useful in the treatment of so-called cold tumors and/or in tumors that are resistant to or acquired resistance to treatment with immune checkpoint modulators. Compounds for use in the disclosed treatment, combinations and methods of treatment are provided.

Provided herein are endothelin receptor antagonistic lasso peptides and related compositions and methods for the management, prevention and/or treatment of an endothelin B receptor (ETBR)-mediated proliferative disease, such as cancer. Biosynthetic methods for producing the lasso peptides are also provided. In some embodiments, the method comprises administering to the subject a therapeutic effective amount of a lasso peptide, wherein the lasso peptide comprises an amino acid sequence selected from SEQ ID NOS:1-17 and 42-56. In particular embodiments, the lasso peptide is GI-D9 cyclized.

Provided are a composition for cell transplant and a method for cell transplant, both of which enable a myocardial tissue to favorably retain cardiac myocytes and/or cardiac progenitors and can improve the persistence and proliferation of transplanted cells. The composition for cell transplant of the present invention is a composition for cell transplant, containing cells and an aqueous solution containing a protein (A), the cells including a cardiac myocyte and/or a cardiac progenitor, the protein (A) having a degree of hydrophobicity of 0.2 to 1.2, the protein (A) containing a polypeptide chain (Y) and/or a polypeptide chain (Y′), the protein (A) containing 1 to 100 polypeptide chains as a total of the polypeptide chain (Y) and the polypeptide chain (Y′), the polypeptide chain (Y) being a polypeptide chain having 2 to 100 continuous amino acid sequences (X), the amino acid sequence (X) having any one of a VPGVG sequence (1) corresponding to an amino acid sequence of SEQ ID NO: 1, a GVGVP sequence (2) corresponding to an amino acid sequence of SEQ ID NO: 2, a GPP sequence, a GAP sequence, and a GAHGPAGPK sequence (3) corresponding to an amino acid sequence of SEQ ID NO: 3, the polypeptide chain (Y′) being a polypeptide chain having a structure in which 0.1 to 5% amino acid residues in the polypeptide chain (Y) are replaced by a lysine residue and/or an arginine residue and including 1 to 100 residues as a total of the lysine residue and the arginine residue.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

It is an object of the present invention to provide a medicament for killing tumor cells, having few side effects. According to the present invention, provided is a medicament for killing tumor cells, comprising: a conjugate of a substance that binds to a target substance on the surface of tumor cells and a cytotoxin; and Talaporfin Sodium, Porfimer Sodium or Verteporfin.

The present invention relates to the use of phycobiliprotein (PBP) to inhibit or treat SARS-CoV-2 infection and COVID 19.

The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.

The subject invention provides compositions and methods for inhibiting viral infections. Preferred embodiments of the invention provide pharmaceutical compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof.

This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.